Chinese team independently developed leukemia-targeted drugs into clinical trials July 11, 2018 Source: China News Author: Wu Lan "The leukemia described in "I am not a drug god" is chronic myeloid leukemia (CML). Our self-developed targeted drugs approved for clinical trials are for patients with acute myeloid leukemia (AML)." Center for Strong Magnetic Science, Chinese Academy of Sciences Researcher Liu Qingsong introduced on the 6th that after five years of clinical trials, it will be a major benefit for the treatment of AML. AML is the most common type of leukemia in adults, and it is also the lowest five-year survival rate among the four major leukemias (AML, CML, ALL, CLL). Most patients with AML die within weeks or months without treatment. Studies have shown that 30% of AML is associated with FLT3 kinase mutations. The world's first clinically applied FLT3 kinase targeting drug, Midostaurin, was approved for marketing in the United States in May 2017. Liu Qingsong said that this is the only personalized targeted therapy with clear molecular typing in the acute myeloid leukemia for more than 20 years, but it causes clinical bone marrow suppression due to its simultaneous inhibition of kinases such as FLT3 and cKIT. It is toxic and causes side effects such as hair whitening, so there is an urgent need for safer and more effective targeted drugs. Liu Qingsong's pharmacology research team of the Strong Magnetic Field Science Center of the Chinese Academy of Sciences, after more than 4 years of basic research and perfect preclinical research, developed a class 1 innovative targeted drug HYML-122 for FLT3-ITD-positive acute myeloid leukemia. According to reports, HYML-122 is a new type of highly selective and highly active FLT3 kinase small molecule inhibitor with independent intellectual property rights. It has applied for Chinese and PCT patent protection. After a complete pre-clinical evaluation, it has shown good drug-forming properties in terms of pharmacology, pharmacokinetics, toxicology and efficacy. In addition, in related animal experiments, bicinchalin has been significantly improved in terms of safety and penetration of solid tumors, and is of great significance for patients with invasive solid tumors in advanced stage of acute myeloid leukemia. The official approval of this phase of clinical trials is also an important milestone in the development of HYML-122. Ready-to-eat Double Packed Sweet Corn
In this category is sweet corn from Jilin Province Agricultural Sister-in-law Food Co.
The physical characteristics of maize consist of grain colour, grain shape, seed coat lustre, grain length, grain width, 100 grain weight, grain diameter, uniformity of the seed and hardness. In most cases, the colour of the endosperm of mature maize kernels is yellow or white, while the seed coat and paste layer are colourless and transparent. Depending on the colour of the kernels, there are three types of maize: yellow, white and mixed. Depending on the kernel form, hardness and different uses, maize is divided into two types: common maize (hard, intermediate, horse-tooth, hard-horse, horse-hard) and special maize (high-lysine maize, high-oil maize, sweet maize, cracked maize, glutinous maize).
The sweet corn of Jilin Province Agricultural Sister-in-law Food Co., Ltd. belongs to the special corn category of yellow corn.
Also known as fruit corn. The leaves on the outside are light green (only the ears are in the pack, we have removed the leaves for you) and the kernels inside are white or yellow. Sweeter than regular sweet corn, but lower in starch and rich in vitamin E and fibre, which is anti-ageing and aids digestion. Perfect for eating raw, mixed with vegetables in salads; it can also be steamed, but don't cook it for too long, about 5 minutes.
If you have any questions, please contact us directly. If you have any questions, please email us directly.
Delectable Sweet Corn Cob,Microwave Sweet Corn Cob,Country Sweet Corn,Ready To Eat Sweet Corn Jilin Province Argricultural Sister-in-law Food Co., Ltd. , http://www.nongsaocorn.com
